QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

BCRX

QT62BioCryst Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
8.99
+0.04+0.45%
OverviewShort InterestFilings
BCRXQT62BioCryst Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
8.99+0.45%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.78
Insider Own2.64%
Shs Outstand254.16M
Perf Week5.76%
Market Cap1.88BForward P/E28.69EPS next Y0.31Insider Trans0.39%Shs Float-Perf Month2.51%
Enterprise Value2.56BPEG0.00EPS next Q0.14Inst Own-Short Float-Perf Quarter-8.36%
Income-396749490.00P/S2.12EPS this Y-50.42%Inst Trans-Short Ratio-Perf Half Y20.35%
Sales885.73MP/B-EPS next Y111.70%ROA-98.48%Short Interest-Perf YTD15.26%
Book/sh-2.18P/C7.30EPS next 5Y-ROE123.57%52W High10.32 -12.89%Perf Year-9.83%
Cash/sh0.94P/FCF6.39EPS past 3/5Y-ROIC-121.96%52W Low6.00 49.83%Perf 3Y-
Dividend Est.-EV/EBITDA-6.87Sales past 3/5Y47.80% 117.44%Gross Margin18.89%Volatility3.13% 2.79%Perf 5Y-
Dividend TTM-EV/Sales2.90EPS Y/Y TTM402.33%Oper. Margin-43.11%ATR (14)0.39Perf 10Y-
Dividend Ex-Date-Quick Ratio1.88Sales Y/Y TTM96.23%Profit Margin-51.71%RSI (14)55.36Recom2.25
Dividend Gr. 3/5Y-Current Ratio1.91EPS Q/Q-SMA204.31%Beta0.87Target Price16.86
Payout0.00%Debt/Eq-1.55Sales Q/Q6.85%SMA500.88%Rel Volume2.05Prev Close8.95
Employees580LT Debt/Eq-3.67EarningsAug 03SMA20013.29%Avg Volume4.33MPrice8.99
IPO DateMar 04, 1994Option/ShortYes / YesEPS/Sales Surpr.-150.00% 3.31%Net Debt/EBITDA-1.84Volume8,881,872Change0.45%
Analyst Ratings
DateActionAnalystRatingTarget
Nov-05-25ReiteratedJMP SecuritiesMarket Outperform$27 → $25
Nov-04-25ReiteratedBarclaysEqual Weight$7.00 → $9.00
Oct-14-25ReiteratedRBC CapitalOutperform$15
Oct-14-25ReiteratedJefferiesBuy$14 → $15
Oct-01-25ReiteratedEvercore ISI$16 → $8.00
Aug-06-24ReiteratedBarclaysEqual Weight$14 → $7.00
Aug-05-24ReiteratedJefferiesBuy$19 → $11
Sep-18-23UpgradeRBC CapitalSector Perform → Outperform
Aug-04-23UpgradeJefferiesHold → Buy
Jul-13-23UpgradeB of A SecuritiesNeutral → Buy
Latest News
Jun-10-26
Jun-10-2606:04PM
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still UnprovenSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue885875451
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A7191912
Gross Profit168856438
Selling, General and Administrative Excl. Other361349266
Research and Development188166175
Other Operating Expense100
Operating Income-382341-3
Interest Expense767999
Unusual Expense
———
Non-Operating Income (Expense)-3-5-14
Net Income Before Taxes-455267-87
Income Taxes342
Consolidated Net Income-458264-89
Net Income From Continuing Operations-458264-89
Net Income-458264-89
EPS (Recurring)-1.731.26-0.43
EPS (Basic, Before Extraordinaries)-1.731.26-0.43
EPS (Diluted)-1.781.21-0.43
EBITDA-37434813
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio—6.45—
Price To Sales Ratio2.461.87—
Gross Margin18.9897.8397.12
Operating Margin-43.1638.97-0.67
Net Margin-51.7530.17-19.73
Shares Outstanding242210207
Market Capitalization2,1761,638—
Operating Lease Expense
———
Insider Trading Volume
$9.78$8.72$7.67$6.61$5.55● Close Price0.00M0.47M0.94M1.41M1.88MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
McKee Amy EDirectorMay 18 '26Sale8.9711,180100,28531,252May 19 12:00 AM
Barnes Alane PChief Legal OfficerMay 13 '26Option Exercise5.04125,000630,000463,203May 15 12:00 AM
Barnes Alane PChief Legal OfficerMay 13 '26Sale9.5462,500596,250400,703May 15 12:00 AM
HEGGIE THERESADirectorMar 20 '26Sale10.1149,933504,82365,352Mar 24 12:00 AM
HEGGIE THERESADirectorMar 20 '26Option Exercise6.3099,866629,156115,285Mar 24 12:00 AM
Barnes Alane PChief Legal OfficerMar 16 '26Sale9.15150,0001,372,500400,703Mar 18 12:00 AM
Barnes Alane PChief Legal OfficerMar 16 '26Option Exercise5.51300,0001,653,000550,703Mar 18 12:00 AM
Stonehouse Jon PDirectorMar 02 '26Option Exercise3.22611,9901,970,6081,629,845Mar 03 12:00 AM
Gayer Charles KPresident and CCODec 22 '25Option Exercise5.01148,466743,792952,583Dec 23 12:00 AM
Barnes Alane PChief Legal OfficerDec 22 '25Sale7.6521,773166,563398,751Dec 23 12:00 AM
Barnes Alane PChief Legal OfficerDec 15 '25Sale7.6521,210162,257315,726Dec 16 12:00 AM
Barnes Alane PChief Legal OfficerDec 03 '25Sale7.6519,770151,241345,476Dec 03 12:00 AM
Barnes Alane PChief Legal OfficerDec 02 '25Sale7.2150,906367,216365,246Dec 03 12:00 AM
Barnes Alane PChief Legal OfficerDec 01 '25Option Exercise3.22182,008586,066507,156Dec 03 12:00 AM
Barnes Alane PChief Legal OfficerDec 01 '25Sale7.1091,004646,511416,152Dec 03 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR